IBD-U Diagnosis Remains Stable for 90% of Patients Long-Term

A long-term study reveals that a diagnosis of Inflammatory Bowel Disease unclassified (IBD-U) is highly stable.

Researchers analyzed 153 patients over several years. At the end of follow-up, 88% remained classified as IBD-U. Only a small percentage were later reclassified as ulcerative colitis or Crohn's disease.

The data shows patients with IBD-U have a unique treatment profile. They use less mesalazine than ulcerative colitis patients but more than Crohn's patients. They are also more likely to receive biologic therapies than ulcerative colitis patients, but less likely than Crohn's patients.

Notably, steroid use and overall healthcare utilization were higher for IBD-U patients compared to those with a definitive diagnosis.

The findings suggest IBD-U is a persistent clinical phenotype, not a temporary diagnostic placeholder. This highlights a need to optimize care and reduce the burden of diagnostic uncertainty for these patients.

The research is based on data from the Leeds IBD Steroid Study.